Press Release

Cutting-Edge Oncolytic Virus Therapy

Children with high grade brain tumors will soon be able to receive cutting-edge onocolytic virus therapy.

International Immunotherapy Clinical Trial

August 24, 2016

Collaborative Research Funding Helps to Advance Innovative New Treatments for Pediatric Brain Tumors 

SKC Formally Appeals NICE Decision

SKC challenged NICE on their decision to deny children the only drug ever specifically developed against neuroblastoma. SKC provided logical arguments against their assessment of cost and efficacy, and championed the plight of these innocent and vulnerable children.  

RACE for Children Act

July 15, 2016
Research to Accelerate Cures and Equity for Children Act

2015 Spring Celebration Raises $650,000

The 6th Annual Spring Celebration was held on June 8 at 583 Park Avenue in New York City. 300 guests attended the event and helped raise $300,000 during the live auction to create three new clinical trials using combination PD-1 inhibitors for children with deadly brain tumors and neuroblastoma.

2015 CCAM

Anonymous Donor Pledges $1 Per Share to Solving Kids` Cancer throughout September

Adoptive transfer of haploidentical natural killer (NK) cells

Scientists will combine NK cell therapy with an immunocytokine to target children with relapsed or refractory disease including those with bulky tumors. 

Harnessing the Power of Natural Killer Cells to Treat Neuroblastoma

Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.

Clinical Trial Opens Using Natural Killer Cells

New York City—(October 10, 2013) Researchers have made rapid advances in understandinghow to manipulate the immune system safely to destroy cancer cells. Adoptive transfer ofhaploidentical natural killer (NK) cells has shown promise as a treatment option to target andkill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will…